Advanced or Metastatic Breast Cancer Clinical Trials

2 recruiting

Advanced or Metastatic Breast Cancer Trials at a Glance

12 actively recruiting trials for advanced or metastatic breast cancer are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Guangzhou, Changchun, and Fuzhou. Lead sponsors running advanced or metastatic breast cancer studies include Shanghai Pharmaceuticals Holding Co., Ltd, Institut Claudius Regaud, and GBG Forschungs GmbH.

Browse advanced or metastatic breast cancer trials by phase

Treatments under study

About Advanced or Metastatic Breast Cancer Clinical Trials

Looking for clinical trials for Advanced or Metastatic Breast Cancer? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced or Metastatic Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced or Metastatic Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 4

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud210 enrolled11 locationsNCT07195344
Recruiting

Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals14,000 enrolled1 locationNCT07476170
Recruiting
Phase 3

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

Locally Advanced or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.912 enrolled1 locationNCT07354022
Recruiting
Phase 1

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC61 enrolled1 locationNCT05187832
Recruiting
Phase 1

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc.70 enrolled8 locationsNCT02926690
Recruiting
Phase 2Phase 3

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd254 enrolled22 locationsNCT05860465
Recruiting
Phase 2

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Advanced or Metastatic Breast CancerBRCA1 MutationBRCA2 Mutation+1 more
GBG Forschungs GmbH176 enrolled36 locationsNCT06201234
Recruiting
Phase 3

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 2

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Fudan University48 enrolled1 locationNCT07182721
Recruiting
Phase 2Phase 3

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd374 enrolled9 locationsNCT05744687
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.180 enrolled1 locationNCT06439771
Recruiting
Phase 3

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Breast NeoplasmsLocally Advanced or Metastatic Breast Cancer
Sun Yat-sen University349 enrolled2 locationsNCT05430399